Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.73 |
| ▸ | DRD4 | P21917 | 4/20 | 0.73 |
| ▸ | DRD2 | P14416 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | CCR3 | P51677 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616449 | 0.93 | ALDH1A1 (0.64) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL31616402 | 0.93 | ALDH1A1 (0.64) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL18657826 | 0.86 | KMT2A (0.77) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL13717362 | 0.85 | SIGMAR1 (0.70) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL18658002 | 0.85 | CCR3 (0.78) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL18657846 | 0.84 | SIGMAR1 (1.00) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL9078087 | 0.84 | DRD4 (1.00) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL14433853 | 0.84 | KMT2A (0.79) | ALDH1A1SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL18657813 | 0.84 | UBE2M (0.75) | ALDH1A1KMT2AKDM4EHSD17B10EPHX2 | |
| SCHEMBL18658202 | 0.84 | DCUN1D1 (0.71) | ALDH1A1SIGMAR1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885SIGMAR1 3671/4885DRD4 2929/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885SIGMAR1 3671/4885DRD4 2929/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885SIGMAR1 3671/4885DRD4 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.